Results 171 to 180 of about 123,913 (326)

Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. [PDF]

J Clin Med, 2022
Szmygin H, Szydełko J, Matyjaszek-Matuszek B.   +2 more
europepmc   +1 more source

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease

, 2016
E. Suárez Castro, Diego Santos‐García, Teresa de Deus Fonticoba, Irene Expósito Ruíz, Cintia Tuñas Gesto, Mercedes Macías Arribí   +5 more
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma

Swiss Medical Weekly, 2006
DL Goede, RS Hauser
doaj   +1 more source

No Dopamine Agonist Modulation of Brain [¹⁸F]FEOBV Binding in Parkinson's Disease. [PDF]

Mol Pharm, 2022
Albin RL, Kanel P, van Laar T, van der Zee S, Roytman S, Koeppe RA, Scott PJH, Bohnen NI.   +7 more
europepmc   +1 more source

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy [PDF]

, 2019
Terri Jerkins, Randy K. Jerkins, Robbi Franklin   +2 more
openalex   +1 more source

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

, 2021
Muzaffar Ali, Lubna Mirza
openalex   +1 more source

Social behavioral profiling by unsupervised deep learning reveals a stimulative effect of dopamine D3 agonists on zebrafish sociality [PDF]

, 2021
Yijie Geng, Randall T. Peterson
openalex   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum. [PDF]

Cells, 2022
Bonate R, Kurek G, Hrabak M, Patterson S, Padovan-Neto F, West AR, Steiner H.   +6 more
europepmc   +1 more source